Wells Fargo & Company Issues Positive Forecast for Hinge Health (NYSE:HNGE) Stock Price

Hinge Health (NYSE:HNGE) had its price target upped by analysts at Wells Fargo & Company from $90.00 to $103.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 16.70% from the company’s current price.

HNGE has been the subject of a number of other reports. Royal Bank Of Canada restated an “outperform” rating and set a $110.00 price objective on shares of Hinge Health in a report on Wednesday. Citizens Jmp lifted their target price on Hinge Health from $96.00 to $107.00 and gave the company a “market outperform” rating in a report on Wednesday. Raymond James Financial boosted their price target on Hinge Health from $70.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. Robert W. Baird upped their price target on Hinge Health from $55.00 to $65.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 17th. Finally, Wall Street Zen downgraded Hinge Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Hinge Health has an average rating of “Moderate Buy” and a consensus price target of $96.33.

Hinge Health Stock Performance

Hinge Health stock traded up $8.84 during trading on Wednesday, reaching $88.26. The company had a trading volume of 1,849,223 shares, compared to its average volume of 1,506,248. Hinge Health has a 12-month low of $30.08 and a 12-month high of $91.50. The stock’s 50 day moving average price is $74.52 and its two-hundred day moving average price is $54.18. The firm has a market capitalization of $6.83 billion, a price-to-earnings ratio of -7.15 and a beta of 1.30.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.31. The company had revenue of $212.82 million for the quarter. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The business’s revenue for the quarter was up 53.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.59 EPS. As a group, research analysts expect that Hinge Health will post 1.37 earnings per share for the current year.

Insider Activity

In related news, major shareholder Insight Holdings Group, Llc sold 1,466,667 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $82.83, for a total transaction of $121,484,027.61. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $60.22, for a total value of $5,018,373.48. Following the transaction, the chairman directly owned 83,334 shares in the company, valued at $5,018,373.48. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,766,556 shares of company stock worth $290,713,052 over the last three months. 18.92% of the stock is currently owned by corporate insiders.

Institutional Trading of Hinge Health

A number of hedge funds have recently made changes to their positions in HNGE. BIT Capital GmbH boosted its stake in shares of Hinge Health by 79.3% in the fourth quarter. BIT Capital GmbH now owns 3,316,101 shares of the company’s stock valued at $154,033,000 after purchasing an additional 1,466,577 shares during the period. Vanguard Group Inc. increased its stake in Hinge Health by 110.5% during the 4th quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company’s stock worth $121,027,000 after buying an additional 1,367,693 shares during the period. Tiger Global Management LLC lifted its holdings in Hinge Health by 227.1% in the 4th quarter. Tiger Global Management LLC now owns 1,805,751 shares of the company’s stock worth $83,877,000 after buying an additional 1,253,743 shares in the last quarter. Millennium Management LLC lifted its holdings in Hinge Health by 225.0% in the 4th quarter. Millennium Management LLC now owns 1,479,642 shares of the company’s stock worth $68,729,000 after buying an additional 1,024,317 shares in the last quarter. Finally, Braidwell LP boosted its position in Hinge Health by 43.3% in the 4th quarter. Braidwell LP now owns 1,304,623 shares of the company’s stock valued at $60,600,000 after buying an additional 394,147 shares during the last quarter.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Strong second-quarter performance: Hinge Health reported $212.8 million in revenue, up 53% year over year, and earnings of $0.59 per share. That exceeded the $0.28 consensus estimate cited by MarketBeat, although Zacks characterized the result as in line with its own consensus. The company also said free cash flow more than tripled from the prior year. Hinge Health reports record second-quarter 2026 financial results
• Positive Sentiment: Above-consensus third-quarter outlook: Management forecast third-quarter revenue of $223 million to $225 million, well above the roughly $211 million analyst consensus. The guidance reinforces expectations for continued strong growth. Hinge Health earnings conference call
• Positive Sentiment: Analyst target raised: Needham increased its price target from $76 to $97 and assigned a “Buy” rating, implying substantial upside from recent trading levels. Benzinga analyst update
• Positive Sentiment: Expansion into gastrointestinal care: Hinge Health agreed to acquire Cylinder Health for $105 million in cash. The deal is intended to add a virtual-first GI Care Program to its existing musculoskeletal and migraine offerings, expanding its addressable market. Hinge Health to acquire Cylinder Health
• Neutral Sentiment: CEO Daniel Perez’s earnings interview and the Q2 earnings call provide additional detail on the company’s operating performance, strategy and outlook. Daniel Perez Hinge Health CEO interview
• Negative Sentiment: Profitability remains a risk: Despite the quarterly EPS beat, Hinge Health continues to report a negative net margin and negative return on equity. The $105 million all-cash acquisition also creates execution and integration risks.

Hinge Health Company Profile

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.